



Patent Application  
Attorney Docket No.PC10770B

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 11<sup>th</sup> day of December 2003

By \_\_\_\_\_

*Irene Grantham*

(Signature of person mailing)  
Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Laura C. Blumberg, et al. :

APPLICATION NO.: 10/660,052 : Examiner: To Be Assigned

FILING DATE: September 9, 2003 : Group Art Unit: To Be Assigned

TITLE: NOVEL PIPERAZINE DERIVATIVES :

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application  
Attorney Docket No.PC10770B

A prompt and favorable response is earnestly solicited.

Date: 12/0/03  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4271

Respectfully submitted,

  
Raymond D. Thompson  
Attorney for Applicant(s)  
Reg. No. 30,695



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10770B	SERIAL NO. 10/660,052
		APPLICANT Laura C. Blumberg, et al.	
		FILING DATE 09/10/03	GROUP To Be Assigned

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	3	1	1	3	2	4	2	1/28/64	Heimlich, et al.	167	82		
	US	3	1	9	2	3	9	7	1/27/03	Peters, et al.	424	20		
	US	3	5	3	8	2	1	4	11/3/70	Polli, et al.	424	19		
	US	4	5	6	5	5	9	8	11/29/77	Groppenbaecher, et al.	424	33		
	US	4	1	7	3	6	2	6	11/6/79	Dempski, et al.	424	19		
	US	6	2	0	7	8	6	5	3/27/01	Bauman, et al.	514	235.8		

#### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER										DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	WO	9	8	5	6	7	7	1	12/17/98	Int'l	C07D	241/00	YES	NO
	WO	9	8	5	6	7	7	1	12/17/98	Int'l	C07D	241/00		

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Cook, et al., "Requirement of MIP-1 $\alpha$ for an Inflammatory Response to Viral Infection", <u>Science</u> 269, pp. 1583-1585 (1995)
		Kuna, et al., "Studies of MCAF/MCP-1, Rantes, MIP-1 alpha, IL-8, Histamine, ECP and Ryptase in Allergic Thinitis Sufferers and Asymptomatic Subjects", <u>J. Allergy Clin. Immunol.</u> 321 (1994)
		Smith, et al., "Production and Function of Murine Macrophage Inflammatory Protein-1 $\alpha$ in Bleomycin-Induced Lung Injury", <u>The Journal of Immunology</u> , pp. 4704-4712 (1994)
		Teran, et al., "Eosinophil Recruitment Following Allergen Challenge Is Associated with the Release of the Chemokine RANTES into Asthmatic Airways", <u>The Journal of Immunology</u> , pp. 1806-1812 (1996)
		Combadiere, et al., "Monocyte Chemoattractant Protein-3 Is a Functional Ligand for CC Chemokine Receptors 1 and 2B", <u>The Journal of Biological Chemistry</u> 270(50), pp. 29671-29675 (1995)
		Coligan, et al., <u>Current Protocols in Immunology</u> , 6.12.1-6.12.3 (John Wiley and Sons, NY, 1991).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.